Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary Disease
Much of the total disease burden and cost of chronic obstructive pulmonary disease (COPD) is associated with acute exacerbations of COPD (AECOPD). Serum amyloid A (SAA) is a novel candidate exacerbation biomarker identified by proteomic screening. To assess SAA as a biomarker of AECOPD. Biomarkers w...
Gespeichert in:
| Veröffentlicht in: | American journal of respiratory and critical care medicine 2008-02, Vol.177 (3), p.269-278 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 278 |
|---|---|
| container_issue | 3 |
| container_start_page | 269 |
| container_title | American journal of respiratory and critical care medicine |
| container_volume | 177 |
| creator | Bozinovski, Steven Hutchinson, Anastasia Thompson, Michelle MacGregor, Lochlan Black, James Giannakis, Eleni Karlsson, Anne-Sophie Silvestrini, Roger Smallwood, David Vlahos, Ross Irving, Louis B Anderson, Gary P |
| description | Much of the total disease burden and cost of chronic obstructive pulmonary disease (COPD) is associated with acute exacerbations of COPD (AECOPD). Serum amyloid A (SAA) is a novel candidate exacerbation biomarker identified by proteomic screening.
To assess SAA as a biomarker of AECOPD.
Biomarkers were assessed (1) cross-sectionally (stable vs. AECOPD; 62 individuals) and (2) longitudinally with repeated measures (baseline vs. AECOPD vs. convalescence; 78 episodes in 37 individuals). Event severity was graded (I, ambulatory; II, hospitalized; III, respiratory failure) based on consensus guidelines.
Presumptively newly acquired pathogens were associated with onset of symptomatic AECOPD. In the cross-sectional study, both SAA and C-reactive protein (CRP) were elevated at AECOPD onset compared with stable disease (SAA median, 7.7 vs. 57.6 mg/L; P < 0.01; CRP median, 4.6 vs. 12.5 mg/L; P < 0.01). Receiver operator characteristics analysis was used to generate area-under-curve values for event severity. SAA discriminated level II/III events (SAA, 0.88; 95% confidence interval, 0.80-0.94 vs. CRP, 0.80; 95% confidence interval, 0.70-0.87; P = 0.05). Combining SAA or CRP with major symptoms (Anthonisen criteria, dyspnea) did not further improve the prediction model for severe episodes. IL-6 and procalcitonin were not informative.
SAA is a novel blood biomarker of AECOPD that is more sensitive than CRP alone or in combination with dyspnea. SAA may offer new insights into the pathogenesis of AECOPD. |
| doi_str_mv | 10.1164/rccm.200705-678OC |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_70238815</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1420274971</sourcerecordid><originalsourceid>FETCH-LOGICAL-c456t-41a4a4b2e6c4eb4f418c2c63885f771f061a54fc9a5a9ebbca169510600b91473</originalsourceid><addsrcrecordid>eNpdkF1rFDEUQIMotq7-AF8kCBX6MDV3JpOPx3Vb20JhBRV8MtxJM27WmUlNZqz77824i4U-JYRzTy6HkNfAzgAEfx-t7c9KxiSrCyHVevWEHENd1QXXkj3NdyargnP97Yi8SGnLGJQK2HNyBIoxoZQ6Jt8_uzj1dNnvuuBv6ZJeJ4r0gw89xp8u0tDSpZ1GRy_-oHWxwdGHIc3Pq00Mg7d03aQxTnb0vx39NHV9GDDu6LlPDpN7SZ612CX36nAuyNePF19WV8XN-vJ6tbwpLK_FWHBAjrwpnbDcNbzloGxpRaVU3UoJLROANW-txhq1axqLIHQNTDDWaOCyWpB3e-9dDL8ml0bT-2Rd1-HgwpSMZGWW5TYL8vYRuA1THPJuBrQWuY-abbCHbAwpRdeau-hzkJ0BZubyZi5v9uXNv_J55s1BPDW9u32YOKTOwMkBwGSxayMO1qf_XJZVElSVudM9t_E_Nvc-OpN67LqsBYPb-WOQ0lSmFLr6C7uDmfg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>199628187</pqid></control><display><type>article</type><title>Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary Disease</title><source>MEDLINE</source><source>American Thoracic Society (ATS) Journals Online</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Bozinovski, Steven ; Hutchinson, Anastasia ; Thompson, Michelle ; MacGregor, Lochlan ; Black, James ; Giannakis, Eleni ; Karlsson, Anne-Sophie ; Silvestrini, Roger ; Smallwood, David ; Vlahos, Ross ; Irving, Louis B ; Anderson, Gary P</creator><creatorcontrib>Bozinovski, Steven ; Hutchinson, Anastasia ; Thompson, Michelle ; MacGregor, Lochlan ; Black, James ; Giannakis, Eleni ; Karlsson, Anne-Sophie ; Silvestrini, Roger ; Smallwood, David ; Vlahos, Ross ; Irving, Louis B ; Anderson, Gary P</creatorcontrib><description>Much of the total disease burden and cost of chronic obstructive pulmonary disease (COPD) is associated with acute exacerbations of COPD (AECOPD). Serum amyloid A (SAA) is a novel candidate exacerbation biomarker identified by proteomic screening.
To assess SAA as a biomarker of AECOPD.
Biomarkers were assessed (1) cross-sectionally (stable vs. AECOPD; 62 individuals) and (2) longitudinally with repeated measures (baseline vs. AECOPD vs. convalescence; 78 episodes in 37 individuals). Event severity was graded (I, ambulatory; II, hospitalized; III, respiratory failure) based on consensus guidelines.
Presumptively newly acquired pathogens were associated with onset of symptomatic AECOPD. In the cross-sectional study, both SAA and C-reactive protein (CRP) were elevated at AECOPD onset compared with stable disease (SAA median, 7.7 vs. 57.6 mg/L; P < 0.01; CRP median, 4.6 vs. 12.5 mg/L; P < 0.01). Receiver operator characteristics analysis was used to generate area-under-curve values for event severity. SAA discriminated level II/III events (SAA, 0.88; 95% confidence interval, 0.80-0.94 vs. CRP, 0.80; 95% confidence interval, 0.70-0.87; P = 0.05). Combining SAA or CRP with major symptoms (Anthonisen criteria, dyspnea) did not further improve the prediction model for severe episodes. IL-6 and procalcitonin were not informative.
SAA is a novel blood biomarker of AECOPD that is more sensitive than CRP alone or in combination with dyspnea. SAA may offer new insights into the pathogenesis of AECOPD.</description><identifier>ISSN: 1073-449X</identifier><identifier>EISSN: 1535-4970</identifier><identifier>DOI: 10.1164/rccm.200705-678OC</identifier><identifier>PMID: 18006888</identifier><language>eng</language><publisher>New York, NY: Am Thoracic Soc</publisher><subject>Acute Disease ; Aged ; Aged, 80 and over ; Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy ; Biological and medical sciences ; Biomarkers - blood ; C-Reactive Protein - analysis ; Chronic obstructive pulmonary disease, asthma ; Cross-Sectional Studies ; Female ; Humans ; Intensive care medicine ; Longitudinal Studies ; Male ; Medical sciences ; Middle Aged ; Pneumology ; Proteomics ; Pulmonary Disease, Chronic Obstructive - blood ; Pulmonary Disease, Chronic Obstructive - diagnosis ; Pulmonary Disease, Chronic Obstructive - physiopathology ; Sensitivity and Specificity ; Serum Amyloid A Protein - metabolism ; Severity of Illness Index ; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><ispartof>American journal of respiratory and critical care medicine, 2008-02, Vol.177 (3), p.269-278</ispartof><rights>2008 INIST-CNRS</rights><rights>Copyright American Thoracic Society Feb 1, 2008</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c456t-41a4a4b2e6c4eb4f418c2c63885f771f061a54fc9a5a9ebbca169510600b91473</citedby><cites>FETCH-LOGICAL-c456t-41a4a4b2e6c4eb4f418c2c63885f771f061a54fc9a5a9ebbca169510600b91473</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4011,4012,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20037183$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18006888$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bozinovski, Steven</creatorcontrib><creatorcontrib>Hutchinson, Anastasia</creatorcontrib><creatorcontrib>Thompson, Michelle</creatorcontrib><creatorcontrib>MacGregor, Lochlan</creatorcontrib><creatorcontrib>Black, James</creatorcontrib><creatorcontrib>Giannakis, Eleni</creatorcontrib><creatorcontrib>Karlsson, Anne-Sophie</creatorcontrib><creatorcontrib>Silvestrini, Roger</creatorcontrib><creatorcontrib>Smallwood, David</creatorcontrib><creatorcontrib>Vlahos, Ross</creatorcontrib><creatorcontrib>Irving, Louis B</creatorcontrib><creatorcontrib>Anderson, Gary P</creatorcontrib><title>Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary Disease</title><title>American journal of respiratory and critical care medicine</title><addtitle>Am J Respir Crit Care Med</addtitle><description>Much of the total disease burden and cost of chronic obstructive pulmonary disease (COPD) is associated with acute exacerbations of COPD (AECOPD). Serum amyloid A (SAA) is a novel candidate exacerbation biomarker identified by proteomic screening.
To assess SAA as a biomarker of AECOPD.
Biomarkers were assessed (1) cross-sectionally (stable vs. AECOPD; 62 individuals) and (2) longitudinally with repeated measures (baseline vs. AECOPD vs. convalescence; 78 episodes in 37 individuals). Event severity was graded (I, ambulatory; II, hospitalized; III, respiratory failure) based on consensus guidelines.
Presumptively newly acquired pathogens were associated with onset of symptomatic AECOPD. In the cross-sectional study, both SAA and C-reactive protein (CRP) were elevated at AECOPD onset compared with stable disease (SAA median, 7.7 vs. 57.6 mg/L; P < 0.01; CRP median, 4.6 vs. 12.5 mg/L; P < 0.01). Receiver operator characteristics analysis was used to generate area-under-curve values for event severity. SAA discriminated level II/III events (SAA, 0.88; 95% confidence interval, 0.80-0.94 vs. CRP, 0.80; 95% confidence interval, 0.70-0.87; P = 0.05). Combining SAA or CRP with major symptoms (Anthonisen criteria, dyspnea) did not further improve the prediction model for severe episodes. IL-6 and procalcitonin were not informative.
SAA is a novel blood biomarker of AECOPD that is more sensitive than CRP alone or in combination with dyspnea. SAA may offer new insights into the pathogenesis of AECOPD.</description><subject>Acute Disease</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</subject><subject>Biological and medical sciences</subject><subject>Biomarkers - blood</subject><subject>C-Reactive Protein - analysis</subject><subject>Chronic obstructive pulmonary disease, asthma</subject><subject>Cross-Sectional Studies</subject><subject>Female</subject><subject>Humans</subject><subject>Intensive care medicine</subject><subject>Longitudinal Studies</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pneumology</subject><subject>Proteomics</subject><subject>Pulmonary Disease, Chronic Obstructive - blood</subject><subject>Pulmonary Disease, Chronic Obstructive - diagnosis</subject><subject>Pulmonary Disease, Chronic Obstructive - physiopathology</subject><subject>Sensitivity and Specificity</subject><subject>Serum Amyloid A Protein - metabolism</subject><subject>Severity of Illness Index</subject><subject>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</subject><issn>1073-449X</issn><issn>1535-4970</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNpdkF1rFDEUQIMotq7-AF8kCBX6MDV3JpOPx3Vb20JhBRV8MtxJM27WmUlNZqz77824i4U-JYRzTy6HkNfAzgAEfx-t7c9KxiSrCyHVevWEHENd1QXXkj3NdyargnP97Yi8SGnLGJQK2HNyBIoxoZQ6Jt8_uzj1dNnvuuBv6ZJeJ4r0gw89xp8u0tDSpZ1GRy_-oHWxwdGHIc3Pq00Mg7d03aQxTnb0vx39NHV9GDDu6LlPDpN7SZ612CX36nAuyNePF19WV8XN-vJ6tbwpLK_FWHBAjrwpnbDcNbzloGxpRaVU3UoJLROANW-txhq1axqLIHQNTDDWaOCyWpB3e-9dDL8ml0bT-2Rd1-HgwpSMZGWW5TYL8vYRuA1THPJuBrQWuY-abbCHbAwpRdeau-hzkJ0BZubyZi5v9uXNv_J55s1BPDW9u32YOKTOwMkBwGSxayMO1qf_XJZVElSVudM9t_E_Nvc-OpN67LqsBYPb-WOQ0lSmFLr6C7uDmfg</recordid><startdate>20080201</startdate><enddate>20080201</enddate><creator>Bozinovski, Steven</creator><creator>Hutchinson, Anastasia</creator><creator>Thompson, Michelle</creator><creator>MacGregor, Lochlan</creator><creator>Black, James</creator><creator>Giannakis, Eleni</creator><creator>Karlsson, Anne-Sophie</creator><creator>Silvestrini, Roger</creator><creator>Smallwood, David</creator><creator>Vlahos, Ross</creator><creator>Irving, Louis B</creator><creator>Anderson, Gary P</creator><general>Am Thoracic Soc</general><general>American Lung Association</general><general>American Thoracic Society</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20080201</creationdate><title>Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary Disease</title><author>Bozinovski, Steven ; Hutchinson, Anastasia ; Thompson, Michelle ; MacGregor, Lochlan ; Black, James ; Giannakis, Eleni ; Karlsson, Anne-Sophie ; Silvestrini, Roger ; Smallwood, David ; Vlahos, Ross ; Irving, Louis B ; Anderson, Gary P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c456t-41a4a4b2e6c4eb4f418c2c63885f771f061a54fc9a5a9ebbca169510600b91473</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Acute Disease</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy</topic><topic>Biological and medical sciences</topic><topic>Biomarkers - blood</topic><topic>C-Reactive Protein - analysis</topic><topic>Chronic obstructive pulmonary disease, asthma</topic><topic>Cross-Sectional Studies</topic><topic>Female</topic><topic>Humans</topic><topic>Intensive care medicine</topic><topic>Longitudinal Studies</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pneumology</topic><topic>Proteomics</topic><topic>Pulmonary Disease, Chronic Obstructive - blood</topic><topic>Pulmonary Disease, Chronic Obstructive - diagnosis</topic><topic>Pulmonary Disease, Chronic Obstructive - physiopathology</topic><topic>Sensitivity and Specificity</topic><topic>Serum Amyloid A Protein - metabolism</topic><topic>Severity of Illness Index</topic><topic>Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bozinovski, Steven</creatorcontrib><creatorcontrib>Hutchinson, Anastasia</creatorcontrib><creatorcontrib>Thompson, Michelle</creatorcontrib><creatorcontrib>MacGregor, Lochlan</creatorcontrib><creatorcontrib>Black, James</creatorcontrib><creatorcontrib>Giannakis, Eleni</creatorcontrib><creatorcontrib>Karlsson, Anne-Sophie</creatorcontrib><creatorcontrib>Silvestrini, Roger</creatorcontrib><creatorcontrib>Smallwood, David</creatorcontrib><creatorcontrib>Vlahos, Ross</creatorcontrib><creatorcontrib>Irving, Louis B</creatorcontrib><creatorcontrib>Anderson, Gary P</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of respiratory and critical care medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bozinovski, Steven</au><au>Hutchinson, Anastasia</au><au>Thompson, Michelle</au><au>MacGregor, Lochlan</au><au>Black, James</au><au>Giannakis, Eleni</au><au>Karlsson, Anne-Sophie</au><au>Silvestrini, Roger</au><au>Smallwood, David</au><au>Vlahos, Ross</au><au>Irving, Louis B</au><au>Anderson, Gary P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary Disease</atitle><jtitle>American journal of respiratory and critical care medicine</jtitle><addtitle>Am J Respir Crit Care Med</addtitle><date>2008-02-01</date><risdate>2008</risdate><volume>177</volume><issue>3</issue><spage>269</spage><epage>278</epage><pages>269-278</pages><issn>1073-449X</issn><eissn>1535-4970</eissn><abstract>Much of the total disease burden and cost of chronic obstructive pulmonary disease (COPD) is associated with acute exacerbations of COPD (AECOPD). Serum amyloid A (SAA) is a novel candidate exacerbation biomarker identified by proteomic screening.
To assess SAA as a biomarker of AECOPD.
Biomarkers were assessed (1) cross-sectionally (stable vs. AECOPD; 62 individuals) and (2) longitudinally with repeated measures (baseline vs. AECOPD vs. convalescence; 78 episodes in 37 individuals). Event severity was graded (I, ambulatory; II, hospitalized; III, respiratory failure) based on consensus guidelines.
Presumptively newly acquired pathogens were associated with onset of symptomatic AECOPD. In the cross-sectional study, both SAA and C-reactive protein (CRP) were elevated at AECOPD onset compared with stable disease (SAA median, 7.7 vs. 57.6 mg/L; P < 0.01; CRP median, 4.6 vs. 12.5 mg/L; P < 0.01). Receiver operator characteristics analysis was used to generate area-under-curve values for event severity. SAA discriminated level II/III events (SAA, 0.88; 95% confidence interval, 0.80-0.94 vs. CRP, 0.80; 95% confidence interval, 0.70-0.87; P = 0.05). Combining SAA or CRP with major symptoms (Anthonisen criteria, dyspnea) did not further improve the prediction model for severe episodes. IL-6 and procalcitonin were not informative.
SAA is a novel blood biomarker of AECOPD that is more sensitive than CRP alone or in combination with dyspnea. SAA may offer new insights into the pathogenesis of AECOPD.</abstract><cop>New York, NY</cop><pub>Am Thoracic Soc</pub><pmid>18006888</pmid><doi>10.1164/rccm.200705-678OC</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1073-449X |
| ispartof | American journal of respiratory and critical care medicine, 2008-02, Vol.177 (3), p.269-278 |
| issn | 1073-449X 1535-4970 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_70238815 |
| source | MEDLINE; American Thoracic Society (ATS) Journals Online; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Journals@Ovid Complete |
| subjects | Acute Disease Aged Aged, 80 and over Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy Biological and medical sciences Biomarkers - blood C-Reactive Protein - analysis Chronic obstructive pulmonary disease, asthma Cross-Sectional Studies Female Humans Intensive care medicine Longitudinal Studies Male Medical sciences Middle Aged Pneumology Proteomics Pulmonary Disease, Chronic Obstructive - blood Pulmonary Disease, Chronic Obstructive - diagnosis Pulmonary Disease, Chronic Obstructive - physiopathology Sensitivity and Specificity Serum Amyloid A Protein - metabolism Severity of Illness Index Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization |
| title | Serum Amyloid A Is a Biomarker of Acute Exacerbations of Chronic Obstructive Pulmonary Disease |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T22%3A51%3A21IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20Amyloid%20A%20Is%20a%20Biomarker%20of%20Acute%20Exacerbations%20of%20Chronic%20Obstructive%20Pulmonary%20Disease&rft.jtitle=American%20journal%20of%20respiratory%20and%20critical%20care%20medicine&rft.au=Bozinovski,%20Steven&rft.date=2008-02-01&rft.volume=177&rft.issue=3&rft.spage=269&rft.epage=278&rft.pages=269-278&rft.issn=1073-449X&rft.eissn=1535-4970&rft_id=info:doi/10.1164/rccm.200705-678OC&rft_dat=%3Cproquest_cross%3E1420274971%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=199628187&rft_id=info:pmid/18006888&rfr_iscdi=true |